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Background. Direct-acting antivirals (DAAs) have revolutionized the treatment of
hepatitis C virus (HCV) infection. Although previous studies have reported positive results
with DAAs after kidney transplantation (KT), their impact on the prevalence of HCV
viremia (HCVv) in prevalent kidney transplant recipients (KTRs) remains ill defined.
Methods. We retrospectively reviewed the HCV status of all patients followed at Clin-
iques Universitaires Saint-Luc, Brussels, Belgium, outpatient KT clinic between January
2014 and December 2018. We collected the clinical features of KTRs treated with
DAAs during this period and calculated the annual prevalence of HCVv over this period.
Results. Out of 1451 KTRs, 22 (1.52%) had HCVv in 2014 to 2018. From 2014 to 2018,
the annual prevalence of HCVv dropped from 1.97% to 0.43%, (P < .001). Fourteen KTRs
were treated with DAAs a median of 197 months (range: 5-374) after KT, mostly (79%) in
2017 after reimbursement restrictions of DAAs for KTRs in Belgium were removed. DAA
treatment was safe with a sustained virological response rate at 12 weeks after treatment
(SVR12) of 93%. Two patients died 14 months (lymphoma, despite SVR12) and 7 months
(hepatocarcinoma, no SVR12) after DAAs initiation, respectively. Among HCVv KTRs
not treated with DAAs (n ¼ 8), 2 lost their graft, 5 died, and 1 is initiating therapy. The
current prevalence of HCVv in the cohort is 0.08%, with a single patient currently on
treatment.
Conclusion. Treatment with DAAs led to a dramatic decrease of HCVv prevalence in this
KTR cohort. DAA use was safe and effective. Elimination of HCV is possible at KT clinics.This study was supported by an unrestricted educational grant
from Merck.
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kanaan@uclouvain.beH EPATITIS C virus (HCV) infection is a leading causeof chronic liver disease and liver-related deaths
worldwide [1,2]. HCV infection affects 1.8% to 15% of
kidney transplant recipients (KTRs) in high-income coun-
tries [3e6], a prevalence up to 10-fold higher than in the
general population [7]. HCV-infected KTRs are at higher
risk of chronic liver disease [8], new-onset diabetes mellitus
[9], a post-transplant lymphoproliferative disorder (PTLD)Authors. Published by Elsevier Inc. This is an open
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2 DEVRESSE, DELIRE, LAZARUS ET AL[10,11], new-onset glomerular diseases [12,13], acute rejec-
tion [14], tuberculosis [15], graft failure, and death [9,16].
Until 2013, the only available treatment for chronic HCV
infection was interferon alfa and ribavirin, which had poor
efficacy [17], especially in patients with chronic kidney dis-
ease (CKD) and genotype 1 infection [18]. In addition, IFN-
based therapy entailed a major risk of acute rejection,
contraindicating its administration after transplantation
[19]. The introduction of direct-acting antivirals (DAAs) for
the treatment of HCV infection is one of the greatest ad-
vances of modern medicine. Treatment with DAAs achieves
sustained virological response (SVR) rates 95% after 8 to
12 weeks of treatment [20]. It has also been demonstrated
that DAAs can be used safely in HCV-infected patients with
CKD with a similar SVR rate [21,22]. In prevalent KTRs, a
randomized trial [23] and case series [24e30] have shown
that DAAs can be used safely in KTRs with SVR 12 weeks
after treatment (SVR12) rates of >90%.
In Belgium, DAAs have been available since 2015.
However, from 2015 to 2017, DAAs were only refunded in
KTRs with a liver fibrosis score F2. DAAs have been fully
refunded for all HCV viremic (HCVv) KTRs (indepen-
dently of liver fibrosis score) since January 2017, and all
reimbursement restrictions were removed in January 2019.
The aims of this single-center retrospective study were to
assess: (1) the annual prevalence of HCVv in KTRs in our
cohort over the last 5 years; and (2) whether the introduction
of DAAs has impacted the prevalence of HCVv in KTRs.MATERIAL AND METHODS
Patient Selection
Between January 2014 and December 2018, 1451 KTRs were fol-
lowed at the outpatient KT clinic in Cliniques Universitaires Saint-
Luc, Brussels, Belgium. HCV serology is performed in all KTRs at
the time of wait-listing, on day of transplantation, and then at least
every 2 years. All KTRs with a confirmed positive HCV serology
(two positive consecutive tests) have a polymerase chain reaction
(PCR) test to detect HCV ribonucleic acid (RNA). Figure 1 shows
the flow chart of the HCVv in KTRs. From the 54 KTRs with a
positive HCV serology, 22 KTRs had HCVv positive PCR during
transplantation (transplanted from December 1985 to March 2017).
Patients were followed until death, allograft failure, or end of the
study.1451 KTR followed at the outpaent clinic 
between 01/2014 and 12/2018
54 KTR with ≥ 1 HCV EIA test confirmed 
posive





Fig 1. Flowchart selection of hepatitis C virus viremic kidney transp
noassay; HCV, hepatitis C virus; IFN, interferon; KTR, kidney transplMicrobiological Investigations
HCV antibody detection was carried out by a qualitative electro-
chemiluminescence immunoassay with the Elecsys Anti-HCV II
assay on the cobas 8000 platform (Roche Diagnostics GmbH,
Penzberg, Germany). HCV viral load was measured by reverse
transcriptase real-time PCR (RT-qPCR) with the Abbott Real-
Time HCV kit on the m2000 system (Abbott, Illinois, United
States).
Prevalence
We calculated the annual prevalence of HCVv in KTRs at the end
of each year, as the ratio between the number of HCVv KTRs and
the total number of patients coming at the outpatient KT clinic at
least once during the year of interest. We assessed the total
number of patients followed at the outpatient KT clinic based on
the Information Technology appointment system: 965 KTRs were
seen at least once in 2014, 996 in 2015, 1015 in 2016, 1006 in 2017,
and 1158 in 2018. Importantly, our local protocol requires that all
KTRs visit our clinic at least once a year. If a KTR died or lost his
or her graft during a year of interest, the patient was included in
the analysis until that year, but not subsequently. If a KTR was
HCV viremic at least 1 day during a year of interest (even if the
KTR was successfully treated during this year), the individual was
considered HCVv positive in the calculation of the annual prev-
alence of that year, but not subsequently. As PCR was not per-
formed repeatedly until DAAs became available, patients were
considered as HCVv from the first positive HCV PCR to post-
treatment laboratory-proven PCR negativation unless a
laboratory-proven spontaneous clearance was assessed (very rare
in immunosuppressed patients) [31].
Statistics
Results are presented as the median and range for continuous
variables. Frequencies of categorical variables are presented as
numbers and percentages. For statistical comparison of the trend of
HCVv prevalence over years, we used the Fisher exact test. Ana-
lyses were performed with R software (version 3.1.3; The R
Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Baseline Characteristics of HCV Viremic KTRs
Table 1 summarizes the baseline characteristics of the
HCVv KTR cohort at transplantation (n ¼ 22). The me-
dian age was 48 (range: 19-70) with 50% female patients.
Causes of end-stage renal disease were glomerulonephritisiremic (n=21)
fully treated before transplantaon (n=10) with IFN (n=7) or DAAs (n=3)
eous resoluon of viremia before transplantaon (n=1)
lant recipients. DAAs, direct-acting antivirals; EIA, enzyme immu-
ant recipient; NAT, nucleic acid testing.
Table 1. Baseline Characteristics of the Hepatitis C Virus Viremic
Cohort at Transplantation
Viremic Population (n ¼ 22)
Age at transplantation, y, median (range) 48 (19-70)
Male recipients, n (%) 11 (50%)
Cause of ESRD, n (%)
Glomerulonephritis 7 (32%)
HCV-mediated GN 1 (5%)
Diabetes mellitus 2 (9%)
ADPKD 3 (14%)
Chronic interstitial nephritis 1 (5%)
Urologic malformation 2 (9%)
Other/undetermined 7 (32%)
First transplantation, n (%) 20 (91%)
Living donor, n (%) 4 (18%)
Isolated kidney transplantation, n (%) 18 (82%)
Combined kidney-pancreas transplantation, n (%) 1 (5%)
Combined liver-kidney transplantation, n (%)* 3 (14%)
HCV genotypes
Unknown, n (%) 1 (5%)
Genotype 1, n (%) 10 (45%)
Genotype 2, n (%) 4 (18%)
Genotype 4, n (%) 6 (27%)
Genotype 3-4 co-infection, n (%) 1 (5%)
Abbreviations: ADPKD, autosomal dominant polycystic kidney disease;
ESRD, end-stage renal disease; GN, glomerulonephritis; HCV, hepatitis C virus.
*Causes of liver transplantation: polycystosis (n ¼ 1), HCV cirrhosis compli-
cated by hepatocarcinoma (n ¼ 2). One patient had a liver transplantation 5
years after the kidney transplantation.
HEPATITIS C IN KIDNEY TRANSPLANT RECIPIENTS 3(32%), diabetes mellitus (9%), autosomal dominant poly-
cystic kidney disease (14%), chronic interstitial nephritis
(5%), urologic malformation (9%), and others/undeter-
mined (32%). For a large majority (91%), it was a first
transplantation, with 18% of KTR transplantation from a
living donor. Only 3 patients underwent combined liver-KT
(1 patient had a liver transplantation 5 years after the KT).
Of these patients, 2 received a liver for HCV-mediated
complication (HCV cirrhosis complicated by hep-
atocarcinoma [HCC]). HCV genotypes were 1 (45%), 2
(18%), 4 (27%), 3-4 co-infection (5%), and unknown (5%),
respectively.Evolution and Management of HCV Viremic KTRs
Twenty-two KTRs were HCVv after transplantation. Four-
teen KTRs were treated with DAAs while having a func-
tioning graft and are described in the following paragraph.
Among those not treated with DAAs (n ¼ 8) (Fig 2), 2
patients (#15 and #22) had lost their grafts in 2014 and
2015, respectively, before full reimbursement availability of
DAAs in Belgium (in 2017). Both were successfully treated
with DAAs while on chronic dialysis after graft loss. Five
KTRs died before DAA treatment initiation (patients #16,
#17, #19, and #20 while listed for DAA treatment, and
patient #21, who died in 2014 before treatment availability)
from septic shock, stroke, heart failure, postoperative
hemorrhagic shock, and undetermined cause, respectively.
Patient #18 has just started DAA treatment.Evolution and Management of HCV Viremic KTRs Treated
With DAAs
Fourteen (64%) KTRs were treated with DAAs while having
a functioning graft, a median of 197 months (range: 5-374)
after transplantation (Table 2). HCV genotypes were type 1
(n¼ 6), type 2 (n¼ 4), and type 4 (n¼ 4). Five combinations
of antivirals had been used: elbasvir/grazoprevir (n ¼ 5),
sofosbuvir/velpatasvir (n¼ 4), sofosbuvir/daclatasvir (n¼ 2),
sofosbuvir/ledipasvir (n ¼ 2), and ombitasvir/paritaprevir/
dasabuvir (n ¼ 1). Treatment initiation rates dramatically
increased in the year 2017 (Table 2 and Fig 2). Out of the 14
treated KTRs, 8 (57%) required calcineurin inhibitor (CNI)
dose adjustment during DAA treatment (5 required CNI
dose reduction and 3 CNI dose increase).
After a median follow-up time of 18 months (range: 6-35)
after DAAs initiation, no patient experienced biopsy-proven
acute rejection or de novo donor-specific antibody occur-
rence after DAA treatment (Table 2 and Fig 2). All patients
had at least 1 anti–human leukocyte antibody assessment by
single-antigen technique after DAA treatment. Median
estimated glomerular filtration rate (calculated by CKD-
Epidemiology Collaboration formula) remained stable af-
ter DAA treatment (44 [range: 30-97] mL/min/1.73 m2
before DAAs initiation vs 45 [range: 23-101] mL/min/1.73
m2 at the end of treatment vs 42 [range: 5-101] mL/min/1.73
m2 at last follow-up), and no KTRs treated with DAAs
experienced graft loss. However, patient #3 experienced
severe allograft dysfunction at the end of follow-up with
imminent need of dialysis. He was a male patient born in
1943 who received a kidney transplant in 1994 for HCV
(genotype 2)-induced cryoglobulinemic glomerulonephritis.
This patient developed heavy proteinuria in 2012, and
allograft biopsy performed in 2014 showed focal and
segmental glomerulosclerosis with no sign of initial disease
recurrence or acute rejection. In September 2017, DAAs
(sofosbuvir/velpatasvir) were initiated and well tolerated.
However, at the time of DAAs initiation, the patient
showed impaired estimated glomerular filtration rate (33
mL/min/1.73 m2) and heavy proteinuria (urine protein/
creatinine ratio at 2.54 g/g). After DAA treatment, allograft
function and proteinuria worsened (Table 2). No allograft
biopsy was performed. At the time of data cut-off, 16
months after DAAs initiation, dialysis was imminent, and
the patient was listed for a second KT.
Two patients died after DAA treatment (Fig 2). Patient #6
was a male patient born in 1949 and received a kidney trans-
plant in 1985 for diabetic nephropathy. He was known since
1994 for HCV genotype 1 viremia without liver enzyme ab-
normalities. In February 2017, DAAs (ledipasvir/sofosbuvir)
were initiated. DAAs were well tolerated without any side ef-
fects, and the patient achieved SVR12. However, in February
2018, the patient reported malaise, decreased appetite,
abdominal pain, andweight loss.RetroperitonealB-cell PTLD
was diagnosed. Because of impaired general status and the
patient’s preference for no aggressive treatment, chemo-
therapy was not initiated, and the patient died 4 months later.






























Fig 2. Clinical evolution of the 22 hepatitis C virus viremic kidney transplant recipients in the 2014 to 2018 period. DAAs, direct-acting
antivirals; HCV, hepatitis C virus; NAT, nucleic acid testing.
4 DEVRESSE, DELIRE, LAZARUS ET ALPatient #7 was a female patient born in 1953 who
received a kidney transplant in 2000 for chronic pyelone-
phritis and subsequently received a liver transplant in 2005
for a genotype 1 HCV-induced HCC. Liver biopsy in June
2015 showed recurrence of HCV hepatitis with a F1
METAVIR score. In January 2016, abdominal magnetic
resonance imaging (MRI) was normal and alpha-
fetoprotein (AFP) level was at 5.8 ng/mL (normal <9 ng/
mL). In October 2016, DAAs (ledipasvir/sofosbuvir) were
initiated and well tolerated. She achieved viral response at
the end of treatment in April 2017. However, SVR12
assessment in July 2017 showed recurrence of HCVv.
Concomitantly, the patient reported general malaise and
abdominal pain. Alpha-fetoprotein level was increased at
41.5 mg/L, and abdominal MRI revealed multiple hepatic
masses compatible with a diffuse HCC, with a high suspicion
of pulmonary metastases at chest x-ray. Biopsy of a hepatic
lesion confirmed HCC diagnosis. The patient died 1 month
later.
With the exception of patient #7, all KTRs treated with
DAAs achieved SVR12 (rate 93%) (Table 2).Annual Prevalence of HCVv in KTRs
The annual prevalence of HCVv in KTRs was 1.97% in
2014, 1.81% in 2015, 1.77% in 2016, 1.69% in 2017, and
0.43% in 2018 (P < .001) (Fig 3). Interestingly, we observed
a dramatic drop of HCVv in 2018 in line with the increasedrate of DAAs initiation in 2017 (Table 2 and Fig 2).
Currently, the prevalence of HCVv in our cohort of KTRs
with functioning graft is 0.08% and will be 0% if the last
patient (#18), who is starting DAA treatment, reaches
SVR12.DISCUSSION
The modification of the Belgian reimbursement of DAAs
has drastically modified the epidemiology of HCVv among
KTRs. Indeed, all HCV-infected KTRs with a functioning
allograft have been treated (1patient still under treatment),
mostly after January 2017. As a consequence, we hope,
HCVv will soon be totally eliminated from our KTR cohort.
DAAs are such a revolution in the management of HCV
infection that the World Health Organization has set the
goal to eliminate HCV in all countries by 2030 [32]. The
optimal strategy to reach this ambitious goal remains
controversial and challenging owing to both the difficulty
organizing effective elimination globally and the high cost of
DAAs, despite recent declines in prices [2]. An economic
analysis revealed that the current prices of DAAs were
globally unaffordable and threaten the sustainability of
many national health systems to eliminate HCV across the
30 countries investigated [33].
The microelimination approach, consisting of first elimi-
nating HCV in well-defined high-risk groups, is another
option. It is less daunting, less complex, and less costly than










































1 1 No 1988 2018 362 F0 SOF/VEL Csa/Aza/st 54 0.09 56 70 0.24 Yes Decrease 6 months
2 2 No 1996 2017 252 F4 SOF/VEL Csa/Aza/st 97 0.15 101 101 0.08 Yes Decrease 23 months
3 2 No 1994 2017 276 F0 SOF/VEL Csa/Aza/st 33 2.54 23 5 8.9 Yes No 16 months,
listed for a
second TP
4 2 No 1988 2017 347 F0-F1 SOF/VEL Csa/MPA/st 71 0.08 79 78 0.14 Yes No 13 months
5 1 No 1990 2016 189 F4 OMB/
PAR/
DASA
Csa/st 43 0.23 42 39 0.41 Yes Decrease 35 months
6 1 No 1985 2017 374 F2 SOF/LED Csa/st 39 0.24 42 42 1.2 Yes Decrease 16 months,
death
(PTLD)
7 1 No 2000 2016 204 F1 SOF/LED Tac 49 0.07 55 57 NA No Increase 11 months,
death
(HCC)
8 1 No 2005 2017 166 F0-F1 ELB/GRA Tac/Aza 30 0.23 28 30 0.13 Yes No 21 months
9 4 Yes 1998 2017 226 F2 ELB/GRA Tac/MPA 38 0.14 35 38 0.67 Yes No 20 months
10 4 Yes 2013 2017 36 F2 ELB/GRA Tac/MPA/st 44 0.54 52 50 0.65 Yes No 20 months
11 4 No 2015 2017 21 F0-F1 SOF/DAC Tac/MPA/st 45 0.22 47 37 0.10 Yes Increase 24 months
12 1 No 2016 2017 7 F0-F1 ELB/GRA Tac/MPA/st 34 0.41 36 38 0.13 Yes Decrease 19 months
13 4 No 2017 2017 5 F0-F1 ELB/GRA Tac/MPA/st 46 0.23 54 62 0.05 Yes Increase 16 months
14 2 No 2004 2017 148 F0 SOF/DAC Tac/MPA/st 40 0.07 41 42 0.10 Yes No 16 months
Abbreviations: Aza, azathioprine; Csa, cyclosporine; CNI, calcineurin inhibitors; DAAs, direct-acting antivirals; eGFR, estimated glomerular filtration rate; ELB/GRA, elbasvir/grazoprevir; EOT, end of treatment; F/U,
follow-up; HCC, hepatocarcinoma; IFN, interferon alfa; IS, immunosuppressive regimen; KT, kidney transplantation; MPA, mycophenolic acid; OMB/PAR/DASA, ombitasvir/paritaprevir/dasabuvir; P/Cr, protein/creatinine;
PTLD, post-transplant lymphoproliferative disorder; st, steroids; SOF/DAC, sofosbuvir/daclatasvir; SOF/LED, sofosbuvir/ledipasvir; SOF/VEL, sofosbuvir/velpatasvir; SVR12, sustained virological response 12 weeks after
treatment; Tac, tacrolimus.






























Fig 3. Evolution of the annual
prevalence of hepatitis C virus
viremic kidney transplant recipients
in the 2014 to 2018 period. HCV,
hepatitis C virus; NAT, nucleic acid
testing.
6 DEVRESSE, DELIRE, LAZARUS ET ALfull-scale, country-level initiatives to eliminate HCV [34]. In
this regard, the transplant and the nephrology communities
have a key role to play regarding the higher reported
prevalence of HCV infection among KTRs and chronic
dialyzed patients compared to the general population
[3e6,22]. In addition, the recently published retrospective
review of the French database showed that in HCV infected
patients, KTRs with detectable HCVv had poorer 10-year
graft and patient survivals compared to matched unaf-
fected controls, while outcomes of patients with undetect-
able viremia were similar to those of patients not infected
[35]. It strongly suggests that DAAs should be proposed to
all KTR and KT candidates.
Our study shows that HCV elimination is possible in
KTRs. All kidney transplant centers should screen and treat
all KTRs with HCVv. Moreover, the 2018 update of the
Kidney Disease Improving Global Outcomes (KDIGO)
guidelines for the management of HCV infection in patients
with CKD recommends treating CKD patients (including
chronic dialyzed patients) with DAAs before KT [36]. This
would translate, in the near future, to the cure of HCV in
kidney transplant candidates before undergoing
transplantation.
DAA treatment was safe and effective in our KTRs with
an SVR12 rate at 93%. None of the patients experienced
acute rejection or de novo donor-specific antibody devel-
opment after DAA treatment. Allograft function also
remained stable. However, as in previous studies, our
follow-up was quite short, and we lack pre- and post-
treatment graft biopsies to explore in-depth if DAAs are
not associated with long-term nephrotoxicity, as recently
suggested by others [37]. In the present study, no graft loss
was observed, but 1 patient (#3) had severe allograft
dysfunction with imminent need for dialysis 16 months afterDAAs initiation. Pre-existing allograft dysfunction and
heavy proteinuria most likely accounted for the end-stage
graft function. However, we cannot totally exclude a po-
tential negative effect of DAA treatment, especially without
histologic information.
In our treated patients, we found that roughly 50% of
patients require dose adjustment during DAA treatment.
This is in agreement with other reports [25,29,38] The
reason is not clearly explained but could reflect enhanced
CNI metabolism associated with improvement of liver injury
[25] or could be an indirect marker of the clearance of
chronic HCV infection that produce pro-inflammatory cy-
tokines that may inhibit cytochrome P450 enzymes [39].
Hence, physicians should closely monitor CNI and adjust
their dose during and after DAA treatment.
If DAA treatment seems safe and effective after KT,
long-term follow-up is still lacking to assess if HCV elimi-
nation after KT can reverse the HCV-related complications.
Even if our cohort of KTRs treated with DAAs is too small
to make solid definitive conclusions, it is important to note
that 2 KTRs died after DAAs treatment of PTLD and HCC,
2 potential HCV-related complications [10,11,40]. HCC is a
dreadful complication and survival after HCC diagnosis in
KTR has been reported to be significantly worse as
compared to nontransplanted patients [41]. The risk of de
novo HCC or HCC recurrence after DAAs is not well
defined, even in the nontransplant setting. Two studies
published in 2016 revealed that the incidences of HCC
recurrence post-DAA treatment or de novo HCC occur-
rence were higher than expected [42,43] Roche et al [44]
recently published a review article in the nontransplant
setting including mostly retrospective studies [44]. The
incidence of de novo HCC after DAAs treatment ranges
from 0.9% to 9.1% and those of HCC recurrence from 12%
HEPATITIS C IN KIDNEY TRANSPLANT RECIPIENTS 7to 29.8%. As a consequence, surveillance for HCC is rec-
ommended with biannual liver imaging for patients with
advanced fibrosis (F3 or F4) who achieve SVR [45]. The
same recommendations apply in the KT setting [36].
One limitation of our study is that it is retrospective,
making it subject to reporting bias. In particular, if an HCVv
KTR did not present to the outpatient KT clinic from 2014
to 2018, the case was missed in the prevalence analysis.
However, this situation seems quite unlikely and marginal.
Also, the follow-up time post-DAA treatment was quite
short (6-35 months), and allograft biopsies were not avail-
able, preventing the assessment of allograft toxicity induced
by DAAs.
In conclusion, treatment with DAAs was safe and effec-
tive in our KTR cohort with a SVR12 rate at 93%. It led to a
dramatic decrease of HCVv prevalence. Elimination of
HCV is finally at reach in this population.
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